Background: The choice of drug treatment in advanced soft tissue sarcoma (STS) continues to be a challenge considering efficacy, QoL and toxicity. Unlike other cancer types, where integrating patient reported outcomes (PRO) has proven to be beneficial for QoL, there is no such evidence in patients with STS yet. Methods: This multi-center study explored the effect of a comprehensive intervention on QoL in patients with STS undergoing treatment with trabectedin (Yondelis V R ). Seven hospitals were cluster-randomized into control cluster (CC with electronic [e] assessment of PRO) or interventional cluster (IC including ePRO and expert-consensus based treatment suggestions). The center, where the multidisciplinary treatment suggestions were created, served as a reference center (RC). Outcomes included QoL (measured with FACT-G), symptoms (MDASI), anxiety and depression (HADS) and pain intensity and interference (BPI). The explorative primary endpoint was change of FACT-G total score (range 0-108) after nine weeks. Results: 80 patients (50% male; mean age: 58.1 years, range: 22-87 years) were included. After nine weeks, decrease in QoL was smaller in IC (-2.04) than in the CC (-5.5) and RC (-4.75). Nevertheless, this trend failed to reach statistical significance (p ¼ 0.235). Improved, but not significant (p ¼ 0.247) median progression free survival was observed in IC (277 days) and CC (279 days) than in RC (126 days). Other PRO showed non-significant, but yet medium to large effects. Conclusions: This is the first study to include ePRO in patients with STS. The clinically important benefit in QoL observed in the IC could serve as a proof of principle to strengthen patient care. Beyond proofing statistical significance of the clinically meaningful effects, this study is an important prerequisite for future research in this area.
Background: The choice of drug treatment in advanced soft tissue sarcoma (STS) continues to be a challenge considering efficacy, QoL and toxicity. Unlike other cancer types, where integrating patient reported outcomes (PRO) has proven to be beneficial for QoL, there is no such evidence in patients with STS yet. Methods: This multi-center study explored the effect of a comprehensive intervention on QoL in patients with STS undergoing treatment with trabectedin (Yondelis V R ). Seven hospitals were cluster-randomized into control cluster (CC with electronic [e] assessment of PRO) or interventional cluster (IC including ePRO and expert-consensus based treatment suggestions). The center, where the multidisciplinary treatment suggestions were created, served as a reference center (RC). Outcomes included QoL (measured with FACT-G), symptoms (MDASI), anxiety and depression (HADS) and pain intensity and interference (BPI). The explorative primary endpoint was change of FACT-G total score (range 0-108) after nine weeks. Results: 80 patients (50% male; mean age: 58.1 years, range: 22-87 years) were included. After nine weeks, decrease in QoL was smaller in IC (-2.04) than in the CC (-5.5) and RC (-4.75) . Nevertheless, this trend failed to reach statistical significance (p ¼ 0.235). Improved, but not significant (p ¼ 0.247) median progression free survival was observed in IC (277 days) and CC (279 days) than in RC (126 days). Other PRO showed non-significant, but yet medium to large effects. Conclusions: This is the first study to include ePRO in patients with STS. The clinically important benefit in QoL observed in the IC could serve as a proof of principle to strengthen patient care. Beyond proofing statistical significance of the clinically meaningful effects, this study is an important prerequisite for future research in this area. Clinical trial identification: NCT02204111. Legal entity responsible for the study: GWT-TUD GmbH. 1607PD Immune response, safety, and overall survival of NY-ESO-11 soft tissue sarcoma patients treated with CMB305 therapy Background: CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T and B cells. It consists of priming with a dendritic cell-targeting lentiviral vector encoding NY-ESO-1, and a boost with NY-ESO-1 recombinant protein plus TLR-4 agonist. This first-in-human study of CMB305 examined safety, immune response (IR), and efficacy in pts with NY-ESO-1 positive (þ) solid tumors. At ASCO2017, median overall survival (OS) for soft tissue sarcoma (STS) was not reached (12 mos OS rate 83%). Methods: Adults with previously treated NY-ESO-1þ solid tumors were enrolled in a 3 þ 3 dose-escalation with an expansion phase 1b study. The CMB305 regimen included 4 intradermal injections of the prime, alternating with 3 intramuscular boost injections over 3 months, then bimonthly boost injections up to 1 yr. An updated STS survival analysis was performed. Results: As of 06 April 2018, 25 pts with STS (15 synovial (SS), 8 myxoid/round cell liposarcoma (MRCL), 2 other) were evaluable for safety; 24 pts were evaluable for IR and efficacy. All pts received prior therapy for advanced disease, 67% > ¼2 prior chemo regimens. No dose limiting toxicities were observed. Most treatment related adverse events were Grade 1 or 2; one Grade 3 (prostatic pain); no grade 4 or 5 events. Best tumor response was stable disease in 8/15 (53%) SS pts and 6/8 (75%) MRCL pts with evidence of tumor growth arrest. The median progression free survival (PFS) was 3.9 mos (2.1, 7.5) for STS and 3.7 mos (2.1, 7.8) for SS. Median OS was 23.7 mos (15.5, NR) for STS and 29.2 mos (12.2, NR) for SS. Presence of anti-NY ESO 1 antibodies (Ab) at baseline (25.0% pts) was associated with longer survival. Anti-NY-ESO-1 specific T cells and Ab developed in 46% and 67% STS pts, respectively. Pts with baseline and induced anti-NY-ESO-1 IR (T-cells and/or antibodies) had a trend to improved clinical outcomes. T cell receptor sequencing indicated increased clonality and antigen spreading was observed. Conclusions: CMB305 is well tolerated, broadly immunogenic, and impacts patient survival favorably when compared with approved agents for recurrent STS. These results support a randomized phase 3 trial evaluating CMB305 in the maintenance setting after 1st line therapy in SS patients. Clinical trial identification: NCT02387125. Legal entity responsible for the study: Immune Design Corp. 
